Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Saved in:
Bibliographic Details
Title: Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
Authors: Ronnacker J; Department of Medicine A, University Hospital Münster, Münster, Germany.; West German Cancer Center (WTZ), Essen-Münster, Germany., Muller PJ; West German Cancer Center (WTZ), Essen-Münster, Germany.; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.; Department of Emergency Medicine, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany., Mikesch JH; Department of Medicine A, University Hospital Münster, Münster, Germany.; West German Cancer Center (WTZ), Essen-Münster, Germany., Zukunft S; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Weinbergerová B; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Šrámek J; Department of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic., Valka J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic., Novak J; University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic., Zak P; Department of Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Szotkowski T; Department of Hematology, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic., Koristek Z; Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic., Krekeler C; Department of Medicine A, University Hospital Münster, Münster, Germany.; West German Cancer Center (WTZ), Essen-Münster, Germany., Unglaub JM; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Sauer T; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Ruhnke L; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Kraus S; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Schaffrath J; Department of Hematology and Oncology, University Hospital Halle, Halle, Germany., Müller LP; Department of Hematology and Oncology, University Hospital Halle, Halle, Germany., Kaes S; Department of Internal Medicine, Hematology and Oncology, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany., Niemann D; Department of Internal Medicine, Hematology and Oncology, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany., Fransecky L; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany., Hess PP; Department of Internal Medicine IV, University Hospital RWTH Aachen, Aachen, Germany., Crysandt M; Department of Internal Medicine IV, University Hospital RWTH Aachen, Aachen, Germany., Jost E; Department of Internal Medicine IV, University Hospital RWTH Aachen, Aachen, Germany., Millo J; Department of Hematology, Oncology and Palliative Medicine, Rems-Murr-Kliniken, Winnenden, Germany., Gaertner J; Department of Internal Medicine 5, Klinikum Nürnberg, Nürnberg, Germany., Repp R; Department of Internal Medicine 2, Städtisches Krankenhaus Kiel, Kiel, Germany., Jentzsch M; Department for Internal Medicine I, University Hospital Leipzig, Leipzig, Germany., Hoppe L; Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany., Klein S; Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany., Modemann F; Department of Oncology and Hematology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Michalowski N; Hospital Pharmacy, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Fischbach K; Department for Hematology, Oncology and Palliative Care, Helios Dr Horst Schmidt Kliniken, Wiesbaden, Germany., Blau W; Department for Hematology, Oncology and Palliative Care, Helios Dr Horst Schmidt Kliniken, Wiesbaden, Germany., Ruhs M; Department of Hematology and Oncology, Kliniken Sindelfingen, Sindelfingen, Germany., Ritter M; Department of Hematology and Oncology, Kliniken Sindelfingen, Sindelfingen, Germany., Lohmeyer J; Department of Hematology and Oncology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Steffen B; Department of Hematology and Oncology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Hauser S; Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch-Hospital, Stuttgart, Germany., Kaufmann M; Department of Hematology and Oncology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Krause SW; Department of Medicine 5 - Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany., Knabe R; Department of Medicine III, University Hospital LMU Munich, Munich, Germany., Spiekermann K; Department of Medicine III, University Hospital LMU Munich, Munich, Germany., Serve H; Department of Hematology and Oncology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Platzbecker U; Department for Internal Medicine I, University Hospital Leipzig, Leipzig, Germany., Baldus CD; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany., Müller-Tidow C; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Lenz G; Department of Medicine A, University Hospital Münster, Münster, Germany.; West German Cancer Center (WTZ), Essen-Münster, Germany., Reinhardt HC; West German Cancer Center (WTZ), Essen-Münster, Germany.; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Mayer J; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Bornhäuser M; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Röllig C; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany., Schliemann C; Department of Medicine A, University Hospital Münster, Münster, Germany. christoph.schliemann@ukmuenster.de.; West German Cancer Center (WTZ), Essen-Münster, Germany. christoph.schliemann@ukmuenster.de., Hanoun M; West German Cancer Center (WTZ), Essen-Münster, Germany. maher.hanoun@uk-essen.de.; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany. maher.hanoun@uk-essen.de.
Source: Leukemia [Leukemia] 2025 Sep; Vol. 39 (9), pp. 2174-2180. Date of Electronic Publication: 2025 Jul 21.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-025-02700-9